Clinical trial NCT05134571: China Post-marketing Surveillance (PMS) Study of Aldurazyme®
Official title: A Phase 4, Single-arm, Open-label Safety and Efficacy Study of Aldurazyme® (Laronidase) as Enzyme Replacement Therapy in Participants With Mucopolysaccharidosis I (MPS I) in China
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Mucopolysaccharidosis I
Keywords: clinical trial
enzyme replacement therapy
mucopolysaccharidosis I
laronidase
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2021-11-26
Enrollment: 12
Sex: ALL
Minimum age (years): 5
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I.

Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate the efficacy of Aldurazyme on the percent change of urinary glycosaminoglycans (uGAGs) from baseline to Week 26. The study will also evaluate the effect on uGAG level and liver volume (hepatomegaly) after 26 weeks, with Aldurazyme treatment in Chinese MPS I participants.

Treatment duration will include: 2 weeks of screening, 26 weeks of treatment and 1 week of follow-up period. During the treatment period, weekly visits are designed to accommodate weekly administration of Aldurazyme (laronidase).

Detailed description: Study duration for each participant will be a total of 29 weeks which will include 2 weeks of screening, 26 weeks of treatment period and 1 week of follow-up period.

Eligibility criteria: Inclusion Criteria:

* Chinese participants have a documented diagnosis of MPS I confirmed by measurable clinical signs and symptoms of MPS I and fibroblast or leukocyte IDUA (iduronidase) activity \<10% of normal.
* Participants have to be able to stand independently and walk a minimum of 5 meters in 6 minutes.
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

  * Is not a woman of childbearing potential (WOCBP).
  * OR
  * Is a WOCBP and agrees to use an acceptable contraceptive method during the intervention period and at a minimum until 7 days after the last dose of study intervention.
  * A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within the screening period before the first dose of study intervention.
  * If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
  * Contraceptive/barrier method is not applicable for male participants.

Exclusion Criteria:

* Prior tracheostomy or bone marrow transplantation or hematopoietic stem cell transplantation.
* Have a plan to undergo bone marrow transplantation or hematopoietic stem cell transplantation within half a year after enrollment.
* Received an investigational drug, or device, other than Aldurazyme, within 30 days prior to study enrollment.
* Received an investigational gene therapy.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Primary outcomes:
measure: Participants with adverse events (AEs)
timeFrame: Baseline to Week 27
measure: The incidence of Potentially clinically significant abnormality (PCSA) analyses for clinical laboratory, vital signs, and ECG parameters during the TE period
timeFrame: Baseline to Week 27
measure: The percent change of uGAGs
timeFrame: Baseline to Week 26
Secondary outcomes:
measure: The percent change of uGAGs
timeFrame: Baseline to Week 2, Week 4, Week 8, Week 12 and Week 20
measure: The absolute change of uGAGs
timeFrame: Baseline to Week 2, Week 4, Week 8, Week 12, Week 20 and Week 26
measure: The percent change of liver volume (Abdominal B type ultrasound examination)
timeFrame: Baseline to Week 26
Other outcomes:
Locations:
city: Beijing
country: China
facility: Investigational Site Number :1560003
city: Beijing
country: China
facility: Investigational Site Number :1560002
city: Guangzhou
country: China
facility: Investigational Site Number :1560004
city: Hangzhou
country: China
facility: Investigational Site Number :1560006
city: Wuhan
country: China
facility: Investigational Site Number :1560001
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References: